The Developability Decision Guide for Nucleic Acid Therapeutics

The Developability Decision Guide for Nucleic Acid Therapeutics

Turning a discovery-stage sequence into a stable, market-ready drug product is where many NAT programs run into trouble. mRNA and other large NATs depend on fragile lipid nanoparticle delivery, while small NATs such as siRNAs and ASOs face self-association and viscosity challenges at the high concentrations subcutaneous dosing demands. Either path can stall a program long before efficacy is ever in question.

Coriolis Pharma’s four-pillar developability framework, covering NAT stability, delivery system, formulation scalability, and post-production logistics, identifies these risks early and maps them against the critical quality attributes that most often catch teams out during scale-up.

Download the decision guide below to see how the framework applies to your modality, and where your program’s specific risks and gaps are likely to sit.

Facing NAT Developability Challenges? Let’s Talk

Whether your NAT candidate is entering formulation development for the first time or has hit an unexpected instability during scale-up, our team can help identify the gap and the fastest route past it.